Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

Myeloproliferative neoplasms (MPN) are debilitating stem cell-derived clonal myeloid malignancies. Conventional treatments for the BCR-ABL1-negative MPN including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) have, so far, been unsatisfactory. Following the...

Descripción completa

Detalles Bibliográficos
Autores principales: Mascarenhas, J, Mughal, TI, Verstovsek, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480698/
https://www.ncbi.nlm.nih.gov/pubmed/22830345
http://dx.doi.org/10.2174/092986712803251511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480698/
https://www.ncbi.nlm.nih.gov/pubmed/22830345
http://dx.doi.org/10.2174/092986712803251511

Ejemplares similares